146 related articles for article (PubMed ID: 37923688)
1. Perspectives of Healthcare Professionals on the Management and Treatment of Advanced Ovarian Cancer in the UK: Results From the KNOW-OC Survey.
Fotopoulou C; Hall M; Lord R; Miller R; Sundar S; Roebuck N; Fildes L; Wesselbaum A; McCormack S; Hickey J; Ledermann J
Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):e1-e10. PubMed ID: 37923688
[TBL] [Abstract][Full Text] [Related]
2. Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.
Duddy M; Wilkinson C; Medhurst S; Rhys K
Mult Scler Relat Disord; 2021 Oct; 55():103174. PubMed ID: 34399317
[TBL] [Abstract][Full Text] [Related]
3. Decision-Making in Gynaecological Oncology Multidisciplinary Team Meetings: A Cross-Sectional, Observational Study of Ovarian Cancer Cases.
Scott R; Hawarden A; Russell B; Edmondson RJ
Oncol Res Treat; 2020; 43(3):70-77. PubMed ID: 31743932
[TBL] [Abstract][Full Text] [Related]
4. Health Care Resource Utilization and Costs Associated with Disease Progression in Ovarian Cancer.
Simmons D; Blank SV; ElNaggar AC; Chastek B; Bunner SH; McLaurin K
Adv Ther; 2022 Jun; 39(6):2544-2561. PubMed ID: 35362863
[TBL] [Abstract][Full Text] [Related]
5. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
[TBL] [Abstract][Full Text] [Related]
6. Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care.
Norell CH; Butler J; Farrell R; Altman A; Bentley J; Cabasag CJ; Cohen PA; Fegan S; Fung-Kee-Fung M; Gourley C; Hacker NF; Hanna L; Høgdall CK; Kristensen G; Kwon J; McNally O; Nelson G; Nordin A; O'Donnell D; Schnack T; Sykes PH; Zotow E; Harrison S
Int J Gynecol Cancer; 2020 Nov; 30(11):1748-1756. PubMed ID: 32784203
[TBL] [Abstract][Full Text] [Related]
7. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.
Vergote I; González-Martín A; Ray-Coquard I; Harter P; Colombo N; Pujol P; Lorusso D; Mirza MR; Brasiuniene B; Madry R; Brenton JD; Ausems MGEM; Büttner R; Lambrechts D;
Ann Oncol; 2022 Mar; 33(3):276-287. PubMed ID: 34861371
[TBL] [Abstract][Full Text] [Related]
8. MDT practice determines treatment pathway for patients with advanced ovarian cancer: A multi-centre observational study.
Khassan T; Smitten E; Wood N; Fotopoulou C; Morrison J; MacDonald M; Baxter K; Edmondson RJ
Eur J Surg Oncol; 2023 Aug; 49(8):1504-1510. PubMed ID: 36958949
[TBL] [Abstract][Full Text] [Related]
9. Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Colombo N; Gadducci A; Landoni F; Lorusso D; Sabbatini R; Artioli G; Berardi R; Ceccherini R; Cecere SC; Cormio G; De Angelis C; Legge F; Lissoni A; Mammoliti S; Mangili G; Naglieri E; Petrella MC; Ricciardi GRR; Ronzino G; Salutari V; Sambataro D; Savarese A; Scandurra G; Tasca G; Tomao F; Valabrega G; Zavallone L; Pignata S
Gynecol Oncol; 2023 Aug; 175():182-189. PubMed ID: 37355448
[TBL] [Abstract][Full Text] [Related]
10. Surgical practice of UK gynaecological oncologists in the treatment of primary advanced epithelial ovarian cancer (PAEOC): a questionnaire survey.
Barton DP; Adib T; Butler J
Gynecol Oncol; 2013 Nov; 131(2):347-51. PubMed ID: 23954901
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
12. Multidisciplinary Team Care of Patients with Hemophilic Arthropathy: A Qualitative Assessment of Contemporary Practice in the UK and Canada : Canada/UK: MDT Practices for Hemophilia.
St-Louis J; Chowdary P; Dolan G; Goodyear D; Strike K; Pollard D; Teitel J
Clin Appl Thromb Hemost; 2022; 28():10760296211070002. PubMed ID: 35060765
[TBL] [Abstract][Full Text] [Related]
13. Impact of COVID-19 pandemic on surgical neuro-oncology multi-disciplinary team decision making: a national survey (COVID-CNSMDT Study).
Price SJ; Joannides A; Plaha P; Afshari FT; Albanese E; Barua NU; Chan HW; Critchley G; Flannery T; Fountain DM; Mathew RK; Piper RJ; Poon MT; Rajaraman C; Rominiyi O; Smith S; Solomou G; Solth A; Surash S; Wykes V; Watts C; Bulbeck H; Hutchinson P; Jenkinson MD;
BMJ Open; 2020 Aug; 10(8):e040898. PubMed ID: 32801210
[TBL] [Abstract][Full Text] [Related]
14. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment.
Zachou G; El-Khouly F; Dilley J
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD006119. PubMed ID: 37650760
[TBL] [Abstract][Full Text] [Related]
16. Nonepithelial ovarian cancer - the current clinical practice in the Nordic countries. Survey from the surgical subcommittee of the Nordic society of gynecological oncology (NSGO).
Daviu C; Blaakaer J; Eriksson AGZ; Herrstedt J; Vandborg MP; Rasmussen AMO; Fuglsang K
Acta Oncol; 2022 Aug; 61(8):939-945. PubMed ID: 35762031
[TBL] [Abstract][Full Text] [Related]
17. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
[TBL] [Abstract][Full Text] [Related]
18. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
[TBL] [Abstract][Full Text] [Related]
19. An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group.
Shimada M; Yoshihara K; Tanigawa T; Nomura H; Hamanishi J; Fujiwara S; Tanabe H; Kajiyama H; Mandai M; Aoki D; Enomoto T; Okamoto A
J Gynecol Oncol; 2023 May; 34(3):e62. PubMed ID: 37116954
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
